149 related articles for article (PubMed ID: 28922455)
21. [Autologous haematopoietic stem cell transplantation in patients with multiple myeloma complicated by dialysis-dependent renal failure].
Firsova MV; Mendeleeva LP; Solovev MV; Rekhtina IG; Pokrovskaya OS; Urnova ES; Soboleva NP; Dvirnyk VN; Klyasova GA; Kuzmina LA; Savchenko VG
Ter Arkh; 2020 Sep; 92(7):70-76. PubMed ID: 33346447
[TBL] [Abstract][Full Text] [Related]
22. Intermediate-dose cytarabine plus G-CSF as mobilization regimen for newly diagnosed multiple myeloma and heavily pre-treated patients with hematological and non-hematological malignancies.
Callera AF; Rosa ES; Callera F
Transfus Apher Sci; 2019 Jun; 58(3):318-322. PubMed ID: 30961974
[TBL] [Abstract][Full Text] [Related]
23. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity.
Gojo I; Guo C; Sarkodee-Adoo C; Meisenberg B; Fassas A; Rapoport AP; Cottler-Fox M; Heyman M; Takebe N; Tricot G
Bone Marrow Transplant; 2004 Jul; 34(1):69-76. PubMed ID: 15133484
[TBL] [Abstract][Full Text] [Related]
24. Remobilization of hematopoietic stem cells with high-dose methotrexate and cytarabine in patients with non-Hodgkin's lymphoma and multiple myeloma after failure to mobilize with chemotherapy and cytokines.
Park SJ; Yoon DH; Kim S; Lee K; Park JS; Jang S; Park CJ; Chi HS; Park CS; Huh J; Suh C
Transfusion; 2014 Mar; 54(3):509-15. PubMed ID: 23800093
[TBL] [Abstract][Full Text] [Related]
25. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
26. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
27. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Terävä V; Putkonen M; Kuittinen T; Pelkonen J; Mäntymaa P; Remes K; Varmavuo V; Jantunen E
Transfusion; 2016 Jun; 56(6):1394-401. PubMed ID: 27041692
[TBL] [Abstract][Full Text] [Related]
28. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
Shimura Y; Kuroda J; Uchiyama H; Kawata-Iida E; Tsutsumi Y; Nagoshi H; Mizutani S; Yamamoto-Sugitani M; Matsumoto Y; Kobayashi T; Horiike S; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
J Clin Apher; 2013 Oct; 28(5):368-73. PubMed ID: 23804501
[TBL] [Abstract][Full Text] [Related]
29. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
[TBL] [Abstract][Full Text] [Related]
30. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
[TBL] [Abstract][Full Text] [Related]
31. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
[TBL] [Abstract][Full Text] [Related]
32. Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.
Benyamini N; Avivi I; Dann EJ; Zuckerman T; Lavi N; Katz T
Ann Hematol; 2017 Mar; 96(3):461-467. PubMed ID: 28013359
[TBL] [Abstract][Full Text] [Related]
33. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
Baertsch MA; Schlenzka J; Lisenko K; Krzykalla J; Becker N; Weisel K; Noppeney R; Martin H; Lindemann HW; Haenel M; Nogai A; Scheid C; Salwender H; Fenk R; Graeven U; Reimer P; Schmidt-Hieber M; Goerner M; Schmidt-Wolf IGH; Klein S; Ho AD; Goldschmidt H; Wuchter P
Eur J Haematol; 2017 Jul; 99(1):42-50. PubMed ID: 28370401
[TBL] [Abstract][Full Text] [Related]
34. The comparison of effectiveness and safety between different biosimilars of G-CSF in the mobilization of peripheral blood stem cells (PBSCs) for autologous transplantation (autologous peripheral blood stem cell transplantation, auto-PBSCT).
Wicherska-Pawłowska K; Rybka J; Prajs I; Szmigiel K; Tyc J; Frączak E; Biedroń M; Kalicińska E; Szymczak D; Wróbel T
J Clin Apher; 2020 Jan; 35(1):4-8. PubMed ID: 31663634
[TBL] [Abstract][Full Text] [Related]
35. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Hart C; Grassinger J; Andreesen R; Hennemann B
Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
[TBL] [Abstract][Full Text] [Related]
36. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization.
Sancho JM; Morgades M; Grifols JR; Juncà J; Guardia R; Vives S; Ferrà C; Batlle M; Ester A; Gallardo D; Millà F; Feliu E; Ribera JM
Cytotherapy; 2012 Aug; 14(7):823-9. PubMed ID: 22540329
[TBL] [Abstract][Full Text] [Related]
37. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
[TBL] [Abstract][Full Text] [Related]
38. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421
[TBL] [Abstract][Full Text] [Related]
39. Local irradiation prior to stem cell harvest has no influence on CD34+ yield: a quantitative analysis.
Rinn JP; Schwella N; Wollmer E; Jaques G; Heinzel-Gutenbrunner M; Strassmann G; Gross MW; Movassaghi K; Neubauer A; Ritter M
Ann Hematol; 2006 Jan; 85(1):38-44. PubMed ID: 16012838
[TBL] [Abstract][Full Text] [Related]
40. Mobilization of peripheral blood stem cells for autologous transplantation patients with hematological malignancies: Influence of disease, mobilization method, age and sex.
Zhang C; Chen X; Zhang X; Gao L; Kong P; Wang Q; Peng X; Liu H
Transfus Apher Sci; 2008 Aug; 39(1):21-8. PubMed ID: 18599353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]